American Capital Management Inc. reduced its stake in Mednax, Inc (NYSE:MD) by 14.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 250,850 shares of the company’s stock after selling 43,885 shares during the period. American Capital Management Inc. owned 0.27% of Mednax worth $15,144,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in the company. First Citizens Bank & Trust Co. bought a new stake in Mednax during the first quarter valued at about $357,000. GW Henssler & Associates Ltd. boosted its stake in Mednax by 12.7% in the first quarter. GW Henssler & Associates Ltd. now owns 152,837 shares of the company’s stock valued at $10,604,000 after buying an additional 17,183 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock valued at $158,000 after buying an additional 102 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Mednax by 0.9% in the first quarter. Retirement Systems of Alabama now owns 175,089 shares of the company’s stock valued at $12,148,000 after buying an additional 1,477 shares in the last quarter. Finally, Hermes Investment Management Ltd. boosted its stake in Mednax by 4.7% in the first quarter. Hermes Investment Management Ltd. now owns 807,096 shares of the company’s stock valued at $55,996,000 after buying an additional 36,545 shares in the last quarter.
Shares of Mednax, Inc (MD) opened at 42.27 on Friday. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of 13.46 and a beta of 0.40. The stock’s 50 day moving average is $51.66 and its 200-day moving average is $60.50. Mednax, Inc has a 1-year low of $41.52 and a 1-year high of $72.13.
Mednax (NYSE:MD) last announced its quarterly earnings results on Friday, July 28th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.03 EPS. On average, analysts anticipate that Mednax, Inc will post $3.31 EPS for the current year.
A number of research analysts have weighed in on MD shares. Jefferies Group LLC reaffirmed a “hold” rating and set a $58.00 price target on shares of Mednax in a research report on Wednesday, April 26th. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Thursday, April 27th. Bank of America Corporation cut shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Finally, Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $55.00 to $68.00 in a research report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company’s stock. Mednax currently has an average rating of “Hold” and a consensus target price of $63.00.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the sale, the director now owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph M. Calabro sold 23,327 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at approximately $16,300,845. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.